Femoral Artery Occlusion, Femoral Artery Stenosis, Popliteal Artery Occlusion, Popliteal Artery Stenosis
Conditions
Keywords
Drug-Eluting Angioplasty Balloon, Drug Coated Angioplasty Balloon, Peripheral Artery Disease, Experimental, Percutaneous Transluminal Angioplasty (PTA)
Brief summary
The purpose of this trial is to assess the safety and efficacy of MDT-2113 for the interventional treatment of de novo and non-stented restenotic lesions in the superficial femoral artery (SFA) and the proximal popliteal artery (PPA) as compared to treatment with standard percutaneous transluminal angioplasty (PTA).
Interventions
DEVICEMDT-2113 Drug-Eluting Balloon
Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
DEVICEStandard angioplasty balloon
Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
Sponsors
Medtronic Endovascular
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
20 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Age: ≥ 20 years and ≤ 85 years * Documented ischemia with Rutherford classification 2, 3, or 4 * Able to walk without assistive devices * Target lesion is in the SFA and/or PPA above the knee * Target lesion consists of a single de novo or non-stented restenotic lesion (or tandem lesions) or is a combination lesion that meets the following criteria: 1. ≥ 70% and \< 100% occluded with total lesion length ≥ 40 mm and ≤ 200 mm 2. 100% occluded with total lesion length ≤100 mm 3. Combination lesions must have total lesion length ≥40 mm and ≤200 mm with an occluded segment that is ≤ 100 mm in length (by visual estimates) * Reference vessel diameter ≥ 4 mm and ≤7 mm (by visual estimate) * Angiographic evidence of adequate distal run-off through the foot
Exclusion criteria
* Stroke or STEMI within the 3 months prior to enrollment * Either local or systemic thrombolytic therapy within the 48 hours prior to the index procedure * Inability to tolerate oral anticoagulation therapy (blood thinners such as warfarin) while on concomitant dual antiplatelet therapy (DAPT) * Known allergies or sensitivities to heparin, aspirin (ASA), other anticoagulant/antiplatelet therapies or to paclitaxel, or an allergy to contrast media that cannot be adequately pre-treated prior to the index procedure * Chronic renal insufficiency * Subject is enrolled in another investigational device, drug, or biologic study * Any major surgical procedure or intervention performed within the 30-day period prior to or post index procedure * Contralateral SFA/PPA disease requiring treatment in the same setting as index procedure * Failure to successfully cross the target lesion * Angiographic evidence of severe calcification * Target lesion known in advance of enrollment to require treatment with alternative therapy such as stenting, laser, atherectomy, cryoplasty, brachytherapy, re-entry devices, cutting balloons, scoring balloons; use of embolic protection devices is also prohibited
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy: Primary patency | 12 month | Primary patency is defined as freedom from clinically-driven target lesion revascularization (TLR) and freedom from restenosis as determined by duplex ultrasound (DUS) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Primary safety endpoint | 12 month | Freedom from device- and procedure-related death through 30 days post-procedure, and freedom from target limb major amputation and clinically-driven target vessel revascularization (TVR) |
Countries
Japan
Outcome results
None listed